Table 3. Cox regression analysis for clinical variables in The Cancer Genome Atlas (TCGA) lung squamous cell carcinoma cohort.
| Clinical characteristics | TCGA ( n = 293) | Univariate | Multivariate | ||
|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | ||
| Age (years, mean ± SD) | 67.72 ± 8.63 | 0.988 (0.962–1.014) | 3.51E−01 | ||
| Gender (Male/Female) | 211/82 | 1.329 (0.783–2.257) | 2.90E−01 | ||
| Pathologic M (0/1/–) | 227/2/64 | 0.303 (0.151–1.536) | 6.07E−01 | ||
| Pathologic N (0/1/2/–) | 193/76/20/4 | 1.562 (1.142–2.138) | 4.72E−03 | 1.011 (0.519–1.854) | 9.53E−01 |
| Pathologic T (1/2/3/4) | 79/159/48/7 | 1.639 (1.209–2.220) | 1.43E−03 | 1.223 (0.749–1.998) | 4.21E−01 |
| Pathologic stage (I/II/III/IV/–) | 139/110/39/2/3 | 1.768 (1.326–2.356) | 7.57E−05 | 1.443 (1.297–2.854) | 2.92E−02 |
| Radiation therapy (Yes/No/–) | 31/251/11 | 2.054 (1.145–3.686) | 1.37E−02 | 1.963 (1.022–3.771) | 4.27E−02 |
| Targeted therapy (Yes/No/–) | 94/188/11 | 1.238 (0.774–1.981) | 3.72E−01 | ||
| PS status (High/Low) | 146/147 | 3.856 (2.297–6.471) | 2.65E−08 | 3.874 (2.256–6.653) | 9.12E−07 |
| Recurrence (Yes/No) | 78/215 | ||||
| RFS time (months, mean ± SD) | 28.28 ± 27.45 | ||||
Note:
CI, confident interval; HR, hazard ratio; SD, standard deviation; RFS, recurrence-free survival; PS, prognostic risk score.